1 member of Congress have disclosed 2 trades in Anavex Life Sciences Corp. (AVXL) since 2022: 1 purchase worth about $8.00K and 1 sale worth about $8.00K. The most active was Chris Jacobs, with 2 trades. The latest trade was made on Dec 12, 2022.
AVXL’s price and SPY’s, both as the change since the start of the range. A green triangle marks a day members bought AVXL, a red one a day they sold; hover for who and how much.
| # | Member | Trades | Buys | Sells | Bought (est.) | Sold (est.) | Net | Buys vs SPY | First Traded | Last Traded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chris JacobsR-NY | 2 | 1 | 1 | $8.00K | $8.00K | $0.00 | -200.2% | Oct 12, 2022 | Dec 12, 2022 |
| Owner | Type | Filing | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chris JacobsR-NY | AVXLAnavex Life Sciences Corp. | Self | Sell | $1K–$15K | Dec 12, 2022 | Jan 20, 2023 | 39d | -86.9% | -175.4% | |
| Chris JacobsR-NY | AVXLAnavex Life Sciences Corp. | Self | Buy | $1K–$15K | Oct 12, 2022 | Nov 16, 2022 | 35d | -89.2% | -200.2% |
Tip. Hover a row for the filing’s full asset text and comments; the PDF link opens the report itself.
1 member of Congress have disclosed 2 trades in Anavex Life Sciences Corp. (AVXL) since 2022: 1 purchase worth about $8.00K and 1 sale worth about $8.00K. The most active was Chris Jacobs, with 2 trades. The latest trade was made on Dec 12, 2022. Most active: Chris Jacobs (2).
Since 2022 they have disclosed 1 purchase and 1 sale; by the midpoints of the disclosed ranges, about $8.00K bought and $8.00K sold, a net purchase of $0.00.
Members of Congress report each trade over $1,000 within 45 days under the STOCK Act, with the amount as a range. The chart marks the days members traded AVXL on its price, against the S&P 500 over the same days.
Members of Congress disclose trades as dollar ranges, up to 45 days after the trade and sometimes later. Volumes use the midpoints of those ranges and are estimates; portfolio figures are a model built from the disclosed trades, not the members’ actual accounts. Not investment advice.